title: Renal denervation after Symplicity HTN-3: an update.
abstract: After three years of excessive confidence, overoptimistic expectations and performance of 15 to 20,000 renal denervation procedures in Europe, the failure of a single well-designed US trial--Symplicity HTN-3--to meet its primary efficacy endpoint has cast doubt on renal denervation as a whole. The use of a sound methodology, including randomisation and blinded endpoint assessment was enough to see the typical 25-30 mmHg systolic blood pressure decrease observed after renal denervation melt down to less than 3 mmHg, the rest being likely explained by Hawthorne and placebo effects, attenuation of white coat effect, regression to the mean and other physician and patient-related biases. The modest blood pressure benefit directly assignable to renal denervation should be balanced with unresolved safety issues, such as potentially increased risk of renal artery stenosis after the procedure (more than ten cases reported up to now, most of them in 2014), unclear long-term impact on renal function and lack of morbidity-mortality data. Accordingly, there is no doubt that renal denervation is not ready for clinical use. Still, renal denervation is supported by a strong rationale and is occasionally followed by major blood pressure responses in at-risk patients who may otherwise have remained uncontrolled. Upcoming research programmes should focus on identification of those few patients with truly resistant hypertension who may derive a substantial benefit from the technique, within the context of well-designed randomised trials and independent registries. While electrical stimulation of baroreceptors and other interventional treatments of hypertension are already "knocking at the door", the premature and uncontrolled dissemination of renal denervation should remain an example of what should not be done, and trigger radical changes in evaluation processes of new devices by national and European health authorities.
authors.affiliation: Pole of Cardiovascular Research, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, Brussels, Belgium, alexandre.persu@uclouvain.be.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Persu
authors.forename: Yu
authors.initials: Y
authors.lastname: Jin
authors.forename: Fadl Elmula Mohamed
authors.initials: FE
authors.lastname: Fadl Elmula
authors.forename: Lotte
authors.initials: L
authors.lastname: Jacobs
authors.forename: Jean
authors.initials: J
authors.lastname: Renkin
authors.forename: Sverre
authors.initials: S
authors.lastname: Kjeldsen
mesh_terms: D001794:Blood Pressure / Q000502:physiology; D002986:Clinical Trials as Topic; D003714:Denervation; D004558:Electric Stimulation; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000503:physiopathology* / Q000628:therapy; D007674:Kidney Diseases / Q000150:complications / Q000503:physiopathology* / Q000601:surgery